BURLINGAME, CA / ACCESS Newswire / July 21, 2025 / Taran Therapeutics ("Taran") a privately held company focused on hematology/oncology, announced additional, statistically significant hematologic ...

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration ...

BOSTON, May 27, 2026 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

Encouraging early results from a SAHMRI-led clinical trial offer new hope to people diagnosed with chronic myelomonocytic leukemia (CMML), a rare and aggressive form of blood cancer. CMML is ...

BOSTON, Dec. 2, 2025 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...

A landmark study published in the Journal of Clinical Oncology has introduced a molecular-based ecosystem that promises to substantially improve the care of patients with chronic myelomonocytic ...

The impact of the use of hypomethylating agents prior to reduced intensity conditioning allogeneic bone marrow transplant among patients with MDS. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Lupus-like manifestations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML) represent a distinct inflammatory syndrome driven by clonal hematopoietic cells rather than ...

A case report describes how persistent monocytosis documented over more than a year led clinicians to reclassify an ...